EXACT Therapeutics Advances Acoustic Therapy for Cancer Care

Promising Outcomes from the Phase 1 ACTIVATE Trial

EXACT Therapeutics is making waves with the encouraging final results from its Phase 1 ACTIVATE trial, demonstrating remarkable potential for its Acoustic Cluster Therapy (ACT®) in patients battling liver metastases from colorectal cancer. The clinical findings suggest that ACT significantly boosts the local efficacy of chemotherapy, paving the way for innovative cancer treatments.

Significant Improvements in Tumor Response

The ACTIVATE trial's results are highly compelling. Among patients who demonstrated a response to chemotherapy, those treated with Acoustic Cluster Therapy showed a substantial tumor reduction, with diameters decreasing by an average of -29%, compared to merely -7% for those receiving chemotherapy alone. This striking difference highlights the enhanced effectiveness of combining ACT with traditional chemotherapy treatments.

Safety Profile and Dosage Insights

Dr. Per Walday, CEO of EXACT Therapeutics, expressed his excitement regarding these findings, which reaffirm the positive safety profile of the treatment. The final analysis aligns with earlier results, indicating a clear dose-response relationship. In patients receiving 40 µl/kg of the proprietary agent PS101, tumor shrinkage was more pronounced compared to those given a lower dose of 20 µl/kg.

Planning for the Future with Phase 2 Trials

These promising results bolster the company's ambitions for its upcoming ENACT Phase 2 trial, which is set to evaluate similar treatment methods for patients grappling with locally advanced or borderline resectable pancreatic cancer. Given the high unmet medical need in this area, the ENACT trial aims to expand the accessibility and effectiveness of ACT treatments in oncology.

ACT Technology and Its Applications

The proprietary Acoustic Cluster Therapy involves administering PS101 via an intravenous route while utilizing ultrasound to optimize the delivery of chemotherapy. This innovative method utilizes microbubbles designed to enhance drug delivery, significantly improving treatment responses in solid tumors. The implications are vast, as ACT can potentially address a variety of cancers beyond colorectal and pancreatic types.

Commitment to Research and Development

EXACT Therapeutics is dedicated to advancing cancer therapies. The company plans to disseminate more detailed results from the ACTIVATE trial in forthcoming scientific publications and medical conferences, contributing to a broader understanding within the scientific community. The team extends its gratitude to the trial participants and investigators for their crucial roles in this groundbreaking study.

What the Future Holds

As EXACT Therapeutics continues to hone its ACT technology, the focus remains on refining therapies that target cancer more effectively and with reduced systemic impact, staying true to their vision of improving patient outcomes through precision medicine.

Frequently Asked Questions

What was the Phase 1 ACTIVATE trial about?

The trial evaluated the safety and efficacy of Acoustic Cluster Therapy combined with chemotherapy for patients with liver metastases from colorectal cancer.

What are the key results of the trial?

The trial showed a significant reduction in tumor sizes with ACT compared to those treated with chemotherapy alone, as well as a positive safety profile.

What is the next step for EXACT Therapeutics?

The company is gearing up for the Phase 2 ENACT trial focused on pancreatic cancer, looking to further validate the efficacy of ACT technology.

How does Acoustic Cluster Therapy work?

ACT utilizes ultrasound and microbubbles to enhance drug delivery directly to tumor sites, which can significantly improve chemotherapy outcomes.

Who can I contact for more information?

For inquiries, please reach out to Per Walday, CEO of EXACT Therapeutics, via email at per.walday@exact-tx.com.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.